AN2 Therapeutics, Inc.
PO Box 417
About AN2 Therapeutics, Inc.
AN2 Therapeutics (AN2) is a biopharmaceutical company focused on developing novel medicines for patients with rare, orphan infectious diseases that represent significant unmet needs. Founded by a team of experienced industry leaders in infectious diseases drug research and development, we strive to provide patients with treatments that will restore their health and enable them to live productive lives.
Our mission is to develop therapeutics to treat rare, chronic, and serious infectious diseases in areas of high unmet medical need. As leaders in the field of antimicrobials, we also have both an obligation and a strong desire to combine our drug discovery and development expertise with resources available from public and private organizations to address high unmet needs in global health.
We are proud to offer a comprehensive and highly competitive benefit package to our employees and their families. From health care and financial benefits, to time off and employee services, our benefits help support our employees’ needs now and in the future.
- Competitive salary and bonus program
- Equity incentive plan
- Medical, dental and vision insurance
- 401K retirement plan
- Flexible paid time off including holidays and sick days
- Life and AD&D insurance
- Employee assistance program
- Short- and long-term disability
At AN2 Therapeutics you’ll find an experienced group of exceptional individuals that share a passion for addressing the challenges of infectious diseases and improving global human health. We employ the industry’s best to create a culture that is fun, respectful, and fulfilling, and where employees feel that they are making a difference and feel inspired to bring their passion to work. Join us in our work to address the challenges of infectious diseases and help us achieve our important and ambitious goals. We look forward to having you apply for a position with the AN2 team!
30 articles about AN2 Therapeutics, Inc.
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 MillionNIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis
AN2 Therapeutics, Inc. today announced the award of a contract valued up to $17.8 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of epetraborole for acute systemic melioidosis.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, reported financial results for the quarter ended June 30, 2022.
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2022.
AN2 Therapeutics, Inc. today announced the appointment of Maggie FitzPatrick to its Board of Directors.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced the appointment of Dr. Mel Spigelman, M.D., to its Board of Directors.
AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to epetraborole for the treatment of infections caused by non-tuberculous mycobacteria (NTM).
AN2 Therapeutics, Inc., today announced topline results from its Phase 1b dose-ranging study of oral epetraborole. AN2 Therapeutics is developing epetraborole.
AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
AN2 Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) application for epetraborole, a once-daily, orally administered investigational treatment for patients with non-tuberculous mycobacterial (NTM) lung disease in December.
AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program
AN2 Therapeutics, Inc. today announced several significant strides in the company's development over the past year.
California-based AN2 Therapeutics secured $80 million in a Series B funding round to help advance its novel nontuberculous mycobacterial lung disease program.